Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bioventus Affirms FY2025 Adj EPS Guidance of $0.64-$0.68 vs $0.66 Est; Affirms FY2025 Sales Guidance of $560.00M-$570.00M vs $564.87M Est

Author: Benzinga Newsdesk | May 06, 2025 07:32am
Bioventus (NASDAQ:BVS) affirms FY2025 Adj EPS guidance from $0.64-$0.68 to $0.64-$0.68 vs $0.66 analyst estimate. Affirms FY2025 sales outlook from $560.00 million-$570.00 million to $560.00 million-$570.00 million vs $564.87 million estimate.

Posted In: BVS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist